Smallpox Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Smallpox is an acute contagious infection caused by the Variola virus. Symptoms include fever, malaise, headache, prostration, severe back pain, abdominal pain, and vomiting. This is followed by the development of rashes on the face, hands, forearms, and trunk. Lesions develop in the mucous membranes of the nose and mouth which ulcerate, releasing large amounts of virus into the mouth and throat. Treatment includes medications such as antiviral and lifestyle modification.

The Smallpox drugs in development market research report provide comprehensive information on the therapeutics under development for Smallpox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects.

Key Targets in the Smallpox Pipeline Products Market

The key targets in the Smallpox pipeline products market are p37 Envelope Protein, 2019 Novel corona Virus Spike Glycoprotein, and DNA.

Smallpox Pipeline Products Analysis Market by Targets

Smallpox Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Smallpox Pipeline Products Market

The key mechanisms of action in the Smallpox pipeline products market are p37 Envelope Protein Inhibitor, 2019 Novel corona Virus Spike Glycoprotein Inhibitor, and DNA Synthesis Inhibitor.

Smallpox Pipeline Products Market Analysis by Mechanism of Actions

Smallpox Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

Key Routes of Administration in the Smallpox Pipeline Products Market

The key routes of administration in the Smallpox pipeline products market are intravenous, topical, oral, intradermal, and subcutaneous.

Smallpox Pipeline Products Market Analysis by Routes of Administration

Smallpox Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Smallpox Pipeline Products Market

The key molecule types in the Smallpox pipeline products market are small molecule, live attenuated vaccine, recombinant vector vaccine, DNA vaccine, monoclonal antibody, subunit vaccine, and vaccine.

Smallpox Pipeline Products Market Analysis by Molecule Type

Smallpox Pipeline Products Market Analysis by Molecule Type

For more molecule type insights, download a free report sample

Major Companies in the Smallpox Pipeline Products Market

The major companies in the Smallpox pipeline products market are SIGA Technologies Inc, Tonix Pharmaceuticals Holding Corp, AlphaVax Inc, Bavarian Nordic A/S, BioFactura Inc, EpiVax Inc, HK inno.N Corp, and Viraze.

Smallpox Pipeline Products Market Analysis by Companies

Smallpox Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Overview

Key targets p37 Envelope Protein, 2019 Novel corona Virus Spike Glycoprotein, and DNA
Key mechanism of action p37 Envelope Protein Inhibitor, 2019 Novel corona Virus Spike Glycoprotein Inhibitor, and DNA Synthesis Inhibitor
Key routes of administration Intravenous, Topical, Oral, Intradermal, and Subcutaneous
Key molecule type Small Molecule, Live Attenuated Vaccine, Recombinant Vector Vaccine, DNA Vaccine, Monoclonal Antibody, Subunit Vaccine, and Vaccine
Major companies SIGA Technologies Inc, Tonix Pharmaceuticals Holding Corp, AlphaVax Inc, Bavarian Nordic A/S, BioFactura Inc, EpiVax Inc, HK inno.N Corp, and Viraze

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Smallpox (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Smallpox (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Smallpox (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Smallpox (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Smallpox (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Smallpox (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Smallpox (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

AlphaVax Inc
Bavarian Nordic A/S
BioFactura Inc
EpiVax Inc
HK inno.N Corp
SIGA Technologies Inc
Tonix Pharmaceuticals Holding Corp
Viraze

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Smallpox – Overview

Smallpox – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Smallpox – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Smallpox – Companies Involved in Therapeutics Development

AlphaVax Inc

Bavarian Nordic A/S

BioFactura Inc

EpiVax Inc

HK inno.N Corp

SIGA Technologies Inc

Tonix Pharmaceuticals Holding Corp

Viraze

Smallpox – Drug Profiles

CJ-40011 – Drug Profile

Product Description

Mechanism Of Action

Jynneos – Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibody for Smallpox – Drug Profile

Product Description

Mechanism Of Action

NIOCH-14 – Drug Profile

Product Description

Mechanism Of Action

smallpox vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

smallpox vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

smallpox vaccine – Drug Profile

Product Description

Mechanism Of Action

ST-357 – Drug Profile

Product Description

Mechanism Of Action

tecovirimat – Drug Profile

Product Description

Mechanism Of Action

History of Events

TNX-1200 – Drug Profile

Product Description

Mechanism Of Action

TNX-1800 – Drug Profile

Product Description

Mechanism Of Action

History of Events

TNX-801 – Drug Profile

Product Description

Mechanism Of Action

History of Events

VIR-002 – Drug Profile

Product Description

Mechanism Of Action

Smallpox – Dormant Projects

Smallpox – Discontinued Products

Smallpox – Product Development Milestones

Featured News & Press Releases

Mar 02, 2022: SIGA announces start of TPOXX post-exposure prophylactic (“PEP”) clinical trials

Jan 10, 2022: SIGA Technologies receives approval from the European Medicines Agency for tecovirimat

Dec 01, 2021: SIGA announces Health Canada regulatory approval of oral TPOXX

Nov 16, 2021: European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) recommends approval of tecovirimat

Sep 07, 2021: SIGA CEO to speak at NCT USA Conference September 8, 2021

Jun 11, 2021: Bavarian Nordic assists public health England in response to new cases of Monkeypox

May 04, 2021: SIGA announces New Drug Application filing with FDA for intravenous formulation of TPOXX

Mar 22, 2021: Bavarian nordic receives additional smallpox vaccine order from the Canadian government

Feb 19, 2021: BioFactura funded $13 million contract option for its smallpox biodefense therapeutic

Jan 13, 2021: SIGA Announces Public Health Agency of Canada contract award to purchase up to approximately $33 million of oral TPOXX

Jan 05, 2021: Bavarian Nordic to supply smallpox vaccines to three European countries

Dec 16, 2020: Bavarian Nordic secures second part of Smallpox Vaccine order from the U.S. Government

Dec 04, 2020: Vaccine genome researchers report

99.7% colinear identity between a U.S. civil war era smallpox vaccine and horsepox virus

Nov 12, 2020: SIGA Technologies Chief Scientific Officer to participate at NCT Asia Virtual Conference

Oct 08, 2020: SIGA announces Public Health Agency of Canada intent to purchase up to 33,300 courses of Oral TPOXX

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Smallpox, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Smallpox – Pipeline by AlphaVax Inc, 2022

Smallpox – Pipeline by Bavarian Nordic A/S, 2022

Smallpox – Pipeline by BioFactura Inc, 2022

Smallpox – Pipeline by EpiVax Inc, 2022

Smallpox – Pipeline by HK inno.N Corp, 2022

Smallpox – Pipeline by SIGA Technologies Inc, 2022

Smallpox – Pipeline by Tonix Pharmaceuticals Holding Corp, 2022

Smallpox – Pipeline by Viraze, 2022

Smallpox – Dormant Projects, 2022

Smallpox – Dormant Projects, 2022 (Contd..1)

Smallpox – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Smallpox, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Smallpox Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Smallpox Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Smallpox Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.